References
Almadrones, L., McGuire, D.B., Walczak, J.R., Florio, C.M., & Tian, C. (2004). Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: A Gynecologic Oncology Group study. Oncology Nursing Forum, 31(3), 615-623.
Armstrong, T., Almadrones, L., & Gilbert, M.R. (2005). Chemotherapy-induced peripheral neuropathy. Oncology Nursing Forum, 32(2), 305-311.
Bauknecht, T., Lueck, H.J., Du Bois, A., Meier, W., Moebus, V., Costa, S., et al. (1997). Interim analysis of a randomized trial comparing cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer [Abstract 715]. Proceedings: American Association for Cancer Research Annual Meeting, 38, 107.
Bril, V. (1999). NIS-LL: The primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy. European Neurology, 41(Suppl. 1), 8-13.
Calhoun, E.A., Welshman, E.E., Chang, C.H., Lurain, J.R., Fishman, D.A., Hunt, T.L., et al. (2003). Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. International Journal of Gynecological Cancer, 13(6), 741-748.
Casey, E.B., Jellife, A.M., Le Quesne, P.M., & Millett, Y.L. (1973). Vincristine neuropathy. Clinical and electrophysiological observations. Brain, 96(1), 69-86.
Cavaletti, G., Bogliun, G., Marzorati, L., Zincone, A., Piatti, M., Colombo, N., et al. (2003). Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology, 61(9), 1297-1300.
Cavaletti, G., Jann, S., Pace, A., Plasmati, R., Siciliano, G., Briani, C., et al. (2006). Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. Journal of the Peripheral Nervous System, 11(2), 135-141.
Cavaletti, G., Tredici, G., Petruccioli, M.G., Donde, E., Tredici, P., Marmiroli, P., et al. (2001). Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. European Journal of Cancer, 37(18), 2457-2463.
Cella, D., Peterman, A., Hudgens, S., Webster, K., & Socinski, M.A. (2003). Measuring the side effects of taxane therapy in oncology: The Functional Assessment of Cancer Therapy-Taxane (FACT-Taxane). Cancer, 98(4), 822-831.
Chaudhry, V., Cornblath, D.R., Corse, A., Freimer, M., Simmons-O'Brien, E., & Vogelsang, G. (2002). Thalidomide-induced neuropathy. Neurology, 59(12), 1872-1875.
Chaudhry, V., Eisenberger, M.A., Sinibaldi, V.J., Sheikh, K., Griffin, J.W., & Cornblath, D.R. (1996). A prospective study of suramin-induced peripheral neuropathy. Brain, 119(Pt. 6), 2039-2052.
Chaudhry, V., Rowinsky, E.K., Sartorius, S.E., Donehower, R.C., & Cornblath, D.R. (1994). Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies. Annals of Neurology, 35(3), 304-311.
Cornblath, D.R., Chaudhry, V., Carter, K., Lee, D., Seysedadr, M., Miernicki, M., et al. (1999). Total Neuropathy Score: Validation and reliability study. Neurology, 53(8), 1660-1664.
du Bois, A., Luck, H.J., Bauknecht, T., Mobus, V., Bochtler, H., Diergarten, K., et al. (1997). Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer. Annals of Oncology, 8(4), 355-361.
Dyck, P.J., Karnes, J., O'Brien, P.C., & Swanson, C.J. (1986). Neuropathy Symptom Profile in health, motor neuron disease, diabetic neuropathy, and amyloidosis. Neurology, 36(10), 1300-1308.
Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. (1999). Journal of the National Cancer Institute, 91(1), 66-72.
England, J.D., Gronseth, G.S., Franklin, G., Miller, R.G., Asbury, A.K., Carter, G.T., et al. (2005). Distal symmetric polyneuropathy: A definition for clinical research: Report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology, 64(2), 199-207.
Feldman, E.L., & Stevens, M.J. (1994). Clinical testing in diabetic peripheral neuropathy. Canadian Journal of Neurological Sciences, 21(4), S3-S7.
Franse, L.V., Valk, G.D., Dekker, J.H., Heine, R.J., & van Eijk, J.T. (2000). "Numbness of the feet" is a poor indicator for polyneuropathy in type 2 diabetic patients. Diabetic Medicine, 17(2), 105-110.
Galer, B.S. (1995). Neuropathic pain of peripheral origin: Advances in pharmacologic treatment. Neurology, 45(12, Suppl. 9), S17-S25.
Galer, B.S. (1998). Painful polyneuropathy. Neurologic Clinics, 16(4), 791-812.
Gregg, R.W., Molepo, J.M., Monpetit, V.J., Mikael, N.Z., Redmond, D., Gadia, M., et al. (1992). Cisplatin neurotoxicity: The relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. Journal of Clinical Oncology, 10(5), 795-803.
Guiheneuc, P., Ginet, J., Groleau, J.Y., & Rojouan, J. (1980). Early phase of vincristine neuropathy in man. Electrophysiological evidence for a dying-back phenomenon, with transitory enhancement of spinal transmission of the monosynaptic reflex. Journal of the Neurological Sciences, 45(2-3), 355-366.
Hagiwara, H., & Sunada, Y. (2004). Mechanism of taxane neurotoxicity. Breast Cancer, 11(1), 82-85.
Hausheer, F.H., Schilsky, R.L., Bain, S., Berghorn, E.J., & Lieberman, F. (2006). Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Seminars in Oncology, 33(1), 15-49.
Hilkens, P.H., & ven den Bent, M.J. (1997). Chemotherapy-induced peripheral neuropathy. Journal of the Peripheral Nervous System, 2(4), 350-361.
Hilkens, P.H., Verweij, J., Stoter, G., Vecht, C.J., van Putten, W.L., & ven den Bent, M.J. (1996). Peripheral neurotoxicity induced by docetaxel. Neurology, 46(1), 104-108.
Kopec, J.A., Land, S.R., Cecchini, R.S., Ganz, P.A., Cella, D., Costantino, J.P., et al. (2006). Validation of a self-reported neurotoxicity scale in patients with operable colon cancer receiving oxaliplatin. Journal of Supportive Oncology, 4(8), W1-W7.
Markman, M. (2006). Chemotherapy-induced peripheral neuropathy: Underreported and underappreciated. Current Pain and Headache Reports, 10(4), 275-278.
Markman, M., Kennedy, A., Webster, K., Kulp, B., Peterson, G., & Belinson, J. (2001). Neurotoxicity associated with a regimen of carboplatin (AUC 5-6) and paclitaxel (175 mg/m2 over 3 h) employed in the treatment of gynecologic malignancies. Journal of Cancer Research and Clinical Oncology, 127(1), 55-58.
Marrs, J., & Newton, S. (2003). Updating your peripheral neuropathy "knowhow." Clinical Journal of Oncology Nursing, 7(3), 299-303.
Ocean, A.J., & Vahdat, L.T. (2004). Chemotherapy-induced peripheral neuropathy: Pathogenesis and emerging therapies. Supportive Care in Cancer, 12(9), 619-625.
Ostchega, Y., Donohue, M., & Fox, N. (1988). High-dose cisplatin-related peripheral neuropathy. Cancer Nursing, 11(1), 23-32.
Pestronk, A., Florence, J., Levine, T., Al-Lozi, M.T., Lopate, G., Miller, T., et al. (2004). Sensory exam with a quantitative tuning fork: Rapid, sensitive and predictive of SNAP amplitude. Neurology, 62(3), 461-464.
Postma, T.J., Aaronson, N.K., Heimans, J.J., Muller, M.J., Hildebrand, J.G., Delattre, J.Y., et al. (2005). The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. European Journal of Cancer, 41(8), 1135-1139.
Postma, T.J., & Heimans, J.J. (1997). Chemotherapy-induced peripheral neuropathy. In P.J. Vecht, G.W. Bruyn, & K.E. Davis (Eds.), Handbook of clinical neurology series. Neuro-oncology: Part III (pp. 459-479). Amsterdam: Elsevier Sciences.
Postma, T.J., Heimans, J.J., Muller, M.J., Ossenkoppele, G.J., Vermorken, J.B., & Aaronson, N.K. (1998). Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Annals of Oncology, 9(7), 739-744.
Quasthoff, S., & Hartung, H.P. (2002). Chemotherapy-induced peripheral neuropathy. Journal of Neurology, 249(1), 9-17.
Ruppert, M., & Croarkin, E. (2003). A review of four vibration sensation assessments used to examine chemotherapy induced neuropathy. Rehabilitation Oncology, 21(3), 11-18.
Russell, J.W., Windebank, A.J., McNiven, M.A., Brat, D.J., & Brimijoin, W.S. (1995). Effect of cisplatin and ACTH4-9 on neural transport in cisplatin induced neurotoxicity. Brain Research, 676(2), 258-267.
Screnci, D., & McKeage, M.J. (1999). Platinum neurotoxicity: Clinical profiles, experimental models and neuroprotective approaches. Journal of Inorganic Biochemistry, 77(1-2), 105-110.
Smith, E.L., Whedon, M.B., & Bookbinder, M. (2002). Quality improvement of painful peripheral neuropathy. Seminars in Oncology Nursing, 18(1), 36-43.
Stillman, M., & Cata, J.P. (2006). Management of chemotherapy-induced peripheral neuropathy. Current Pain and Headache Reports, 10(4), 279-287.
Sweeney, C.W. (2002). Understanding peripheral neuropathy in patients with cancer: Background and patient assessment. Clinical Journal of Oncology Nursing, 6(3), 163-166.
Verstappen, C.C., Heimans, J.J., Hoekman, K., & Postma, T.J. (2003). Neurotoxic complications of chemotherapy in patients with cancer: Clinical signs and optimal management. Drugs, 63(15), 1549-1563.
Vileikyte, L., Peyrot, M., Bundy, C., Rubin, R.R., Leventhal, H., Mora, P., et al. (2003). The development and validation of a neuropathy- and foot ulcerspecific quality of life instrument. Diabetes Care, 26(9), 2549-2555.
Visovsky, C. (2003). Chemotherapy-induced peripheral neuropathy. Cancer Investigation, 21(3), 439-451.
Wampler, M.A., Miaskowski, C., Hamel, K., Byl, N., Rugo, H., & Topp, L.S. (2006). The modified Total Neuropathy Score: A clinically feasible and valid measure of taxane-induced peripheral neuropathy in women with breast cancer. Journal of Supportive Oncology, 4, W9-W16.